Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Marappan (Chennai, India). Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma. Eur Respir J 2007; 30: Suppl. 51, 3652

Member's Comments

No comment yet.

Related content which might interest you: Clinical efficiency of sublingual and subcutaneous allergenspecific immunotherapy with household dust mite allergen in patients with persistent allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 438s Year: 2006 Effect of house dust mite sublingual immunotherapy on airway inflammation and remodeling in allergic asthma with rhinitis Source: International Congress 2019 – Precision meets immunology in treatment of airway diseases Year: 2019 Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 Diagnostic utility of serum periostin for house dust mite sublingual immunotherapy response in allergic rhinitis Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021 Impact of asthma-associated genetic polymorphisms on the efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021 Specific allergen immunotherapy of asthma combined with allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006 Efficacy of specific allergy vaccination in house dust mite asthma Source: Eur Respir J 2005; 26: Suppl. 49, 465s Year: 2005 Safety of subcutaneous immunotherapy with standardized extracts of house dust mite in allergic asthmatic subjects Source: Eur Respir J 2002; 20: Suppl. 38, 57s Year: 2002 Circulating platelets activity in patients sensitised to house dust mite suffering from persistent allergic rhinitis with or without asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 590s Year: 2005 Evaluation of six-year allergen immunotherapy in allergic rhinitis and allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 439s Year: 2006 Hypoallergenic high dose scit as add-on therapy in children with allergic asthma caused by house dust mites Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009 Calcaratarin D attenuates house dust mite-induced allergic asthma Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 Effects of 3-yr immunotherapy with standardised extracts of house dust mite in allergic asthmatic subjects receiving appropriate drug treatment Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002 OPURIT: Omalizumab-protected ultra rush specific immunotherapy in severe asthmatic patients with house dust mite allergy Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 High-altitude treatment in atopic and nonatopic patients with severe asthma Source: Eur Respir J 2012; 40: 1374-1380 Year: 2012 The effect of BCG treatment on the remodelling in the house dust mite induced allergic asthma in mice Source: Eur Respir J 2005; 26: Suppl. 49, 580s Year: 2005 Allergen exposure in nondog and nonhouse dust mite sensitized atopic asthmatic subjects; effect on bronchial reactivity Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001 Sublingual monomeric allergoid immunotherapy improves airway inflammation, airway hyperresponsiveness and clinical symptoms in allergic rhinitis and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 439s Year: 2006